Multiomics profiling of enoxaparin never responders. (A) Twenty-six patients were identified as never responders to enoxaparin therapy. Among these, 18 patients did not develop VTE, whereas 8 patients developed VTE (purple). (B) Ranked log2-transformed median protein abundances for the never responders, grouped by VTE development status. (C) Similarly, ranked log2-transformed median metabolite abundances displayed for the never responders, grouped by VTE development status. (D) PLS-DA was used to classify the integrated metabolomic and proteomic signatures of patients based on VTE development status. (E) The top 25 molecular features identified by the PLS-DA model contributed to the differentiation between VTE development status groups. (F) Heat map depicting the top 50 molecular features that showed significant differences between the VTE development status groups, as determined by the t test. Feature names were colored according to key thromboinflammatory pathways of interest to this analysis. Orange, complement activation; red, blood coagulation; dark blue, immune response; light blue, acute phase response. The analysis incorporated data from all time points.